Evidence map›Paper›PMID 17551006›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2007

Systematic prediction and validation of breakpoints associated with copy-number variants in the human genome.

Jan O Korbel, Alexander Eckehart Urban, Fabian Grubert, Jiang Du, Thomas E Royce, Peter Starr, Guoneng Zhong, Beverly S Emanuel, Sherman M Weissman, Michael Snyder and 1 more

Abstract readComparative Study
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Examination of Smad2 and Smad4 copy-number variations in skin cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2012
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jan O KorbelDepartments of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520, USA. jan.korbel@yale.edu
Alexander Eckehart Urban
Fabian Grubert
Jiang Du
Thomas E Royce
Peter Starr
Guoneng Zhong
Beverly S Emanuel
Sherman M Weissman
Michael Snyder
Mark B Gerstein

Funding

Human Genome Array: Technology for Functional AnalysisP50HG002357 · NHGRI · YALE UNIVERSITY · PI SNYDER, MICHAEL P. · 2001 to 2010
$31.9M
YALE BIOMEDICAL SUPERCOMPUTER: NEUROSCIENCES10RR019895 · NCRR · YALE UNIVERSITY · PI WILLIAMS, KENNETH ROBERT · 2004 to 2004
$1.6M
NCRR NIH HHS RR 19895-02NCRR NIH HHS S10 RR019895NHGRI NIH HHS P50 HG002357NHGRI NIH HHS P50 HG 02357-01
6 · The paper itself

Abstract

Copy-number variants (CNVs) are an abundant form of genetic variation in humans. However, approaches for determining exact CNV breakpoint sequences (physical deletion or duplication boundaries) across individuals, crucial for associating genotype to phenotype, have been lacking so far, and the vast majority of CNVs have been reported with approximate genomic coordinates only. Here, we report an approach, called BreakPtr, for fine-mapping CNVs (available from http://breakptr.gersteinlab.org). We statistically integrate both sequence characteristics and data from high-resolution comparative genome hybridization experiments in a discrete-valued, bivariate hidden Markov model. Incorporation of nucleotide-sequence information allows us to take into account the fact that recently duplicated sequences (e.g., segmental duplications) often coincide with breakpoints. In anticipation of an upcoming increase in CNV data, we developed an iterative, "active" approach to initially scoring with a preliminary model, performing targeted validations, retraining the model, and then rescoring, and a flexible parameterization system that intuitively collapses from a full model of 2,503 parameters to a core one of only 10. Using our approach, we accurately mapped >400 breakpoints on chromosome 22 and a region of chromosome 11, refining the boundaries of many previously approximately mapped CNVs. Four predicted breakpoints flanked known disease-associated deletions. We validated an additional four predicted CNV breakpoints by sequencing. Overall, our results suggest a predictive resolution of approximately 300 bp. This level of resolution enables more precise correlations between CNVs and across individuals than previously possible, allowing the study of CNV population frequencies. Further, it enabled us to demonstrate a clear Mendelian pattern of inheritance for one of the CNVs.

Indexed as

Chromosome BreakageChromosomes, Human, Pair 11Chromosomes, Human, Pair 22Gene DosageGenetic VariationGenome, HumanAlgorithmsBase SequenceHumansModels, GeneticMolecular Sequence DataNucleic Acid HybridizationOligonucleotide Array Sequence AnalysisPhysical Chromosome MappingPolymerase Chain ReactionPolymorphism, Genetic

Identifiers

PMID17551006
PMCPMC1891248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.